

Article Review - Virus-Like Particles: A Comprehensive Review of Design, Applications, and Future Directions

Ali Sabri Jabbar¹ and Ahmed Majeed Abdzaid²

¹Lecturer, College of Pharmacy, University of Al-Qadisiyah, Al-Qadisiyah, IRAQ

²Lecturer, Department of Pathological Analysis, College of Science, University of Al-Qadisiyah, Al-Qadisiyah, IRAQ

²Corresponding Author: ahmed.majeed@qu.edu.iq



www.sjmars.com || Vol. 3 No. 3 (2024): June Issue

Date of Submission: 26-06-2024

Date of Acceptance: 29-06-2024

Date of Publication: 02-07-2024

ABSTRACT

Virus-like particles (VLPs) are no longer a new approach, but rather a transformative force in vaccine development. These marvels of engineering mimic the structure of viruses, but lack the crucial genetic material for replication. This translates to a powerful one-two punch: safety and effectiveness. VLPs can be meticulously designed to target a wide range of diseases, from established threats like HPV and HBV to the ever-present challenge of cancer. Their versatility extends even further, with ongoing research exploring their potential against emerging infectious diseases like COVID-19. However, the road to VLP-based vaccines isn't without its hurdles. Manufacturing these particles can be intricate and expensive, and ensuring their stability during storage remains a challenge. Additionally, some viruses mutate rapidly, rendering vaccines targeting specific strains less effective. Undeterred, researchers are actively tackling these obstacles. Advancements in genetic engineering, nanotechnology, and adjuvants (compounds that enhance immune response) hold great promise for making VLP vaccines even more potent and adaptable. The future may even see VLPs joining forces with other vaccine platforms, like mRNA vaccines, creating a new generation of powerful and versatile tools for disease prevention. The present review article aimed to highlight different aspects of VLPs including their design, advantages, challenges, and future.

Keywords- Virus-like particles, vaccines, vaccine design.

I. INTRODUCTION

Recent advances immunization technology revolutionized Virus-like particles (VLPs) that is novel immunization approach which has developed as a revolutionary tool in advancement of vaccine, presenting a promising immunization strategy. There is no genetic material in VLPs particles responsible for replication, they are mimicking the structure of viruses enabling them to elicit highly effective and safe immune responses. The present review article aimed to highlight the design, benefits, challenges, and future prospects of VLP-based vaccines. [1]

II. STRUCTURE AND DESIGN OF VLPS

VLPs particles are proteins of viral origin that self-assemble into particles like the original viruses such as proteins derived from capsid or envelope of viruses like human papillomavirus (HPV), influenza virus, and hepatitis B virus (HBV), they consider the most common proteins used in construction of VLPs. These proteins may be produced in different organisms including bacteria, yeast, insect cells, and mammalian cells, each of which presenting different function according to their yield based on post-translational modifications and scalability [1][2].

III. ADVANTAGES OF VLP-BASED VACCINES

3.1. Safety

Safety profile is one of the crucial considerations of VLPs. there are no threat of infection or genetic recombination of host genomes, their structure lacks viral genetic material which is a distinctive characteristic makes VLP-based vaccines particularly appropriate for immunocompromised individuals and pregnant women [3].

3.2. Immunogenicity

To trigger immune system, particles need repetitive and particulate nature which are the distinctive features of VLPs, they elicit both humoral and cellular immune response effectively, furthermore, their epitopes are displayed onto surfaces of antigen presenting cells in manner mimics the natural viral infection triggering efficient B-cell and T-cell activation [4][5].

3.3. Flexibility and Versatility

VLPs designing module offers a revolutionary approach to vaccine development by allowing the flexible incorporation of antigens from diverse pathogens, this technology paves the way for the creation of multivalent vaccines. This is particularly advantageous in tackling complex diseases like HIV, malaria, and cancer, where a single antigen may not provide sufficient protection [6].

IV. APPLICATIONS OF VLP-BASED VACCINES

4.1. Prophylactic Vaccines

To date, application of VLPs that has been developed successfully is prophylactic vaccines, the most common VLP-based licensed vaccines are HPV vaccine, Gardasil, and the HBV vaccine, Engerix-B, that are highly effective and safe in preventing of such infections. [7][8].

4.2. Therapeutic Vaccines

Cancer immunotherapy, is one of the therapeutic applications of VLP-based vaccines. Therapeutic VLP-based vaccines targets being to trigger an immune response against tumor-associated antigens, destructing cancer cells. Promising beneficial results have obtained in preclinical and clinical trials for various cancers, including cervical, cancer melanoma, and prostate cancer [9][10].

4.3. Emerging Infectious Diseases

Through rapidly emerging pandemic of COVID-19, VLPs approach offered an outstanding response, VLP-based platforms is one of the first to use to develop the viral vaccine. Due to their facilitated manufacturability and capacity to elicit potent immune activation, VLPs emerged as promising vaccine candidates for outbreak scenarios [11][12].

V. CHALLENGES IN VLP VACCINE DEVELOPMENT

5.1. Manufacturing and Scalability

There are particular challenges have obtained in manufacturing of VLPs in spite of their benefits. They are complex in the expression of protein and the requirement of precise folding and assembly which need a complex and conducted manufacturing processes. Furthermore, achieving consistent production with quality across batches is paramount for regulatory acceptance [13][14].

5.2. Stability and Storage

Stability of biological products like VLP-based under **Storage and** environmental conditions such as temperature and pH is one of important challenge in development of this vaccines particularly in regions of poor cold infrastructure [15].

5.3. Immune Evasion and Antigenic Variation

Frequent genetic variations viruses like influenza and HIV viruses presenting an important challenge in the VLP vaccine designation. Viral Antigenic variation enabling them to evade host immune requiring frequent update in vaccine formulations to be effective to new emerged strains. Incorporating of conserved antigenic determinants and adjuvants use, are explored to overcome these challenges [16][17].

VI. FUTURE PROSPECTS AND INNOVATIONS

The future of VLP-based vaccines is brimming with promise, fueled by ongoing research that delves into augmenting their efficacy and broadening their applicability. Advancements in the realms of genetic engineering, nanotechnology, and adjuvant development are anticipated to propel the design and delivery of VLP vaccines. Furthermore, the synergistic integration of VLPs with pioneering platforms like mRNA vaccines holds the potential to usher in a new era of vaccines characterized by unparalleled potency and versatility [18].

VII. CONCLUSION

VLPs offer a crucial development in vaccine approaches technology, presenting an effective, safe, and versatile immunization approach. In spite of challenges is sill, the development of VLP-based vaccines has a great potential to prevent and to treat a wide spectrum of infectious diseases. The successful VLP vaccines, engaged with ongoing innovations, highlight their impact to revolutionize vaccine design in the future.

REFERENCES

- [1] Pattenden LK, Middelberg AP, Niebert M, Lipin DI. Towards the preparative and large-scale precision manufacture of virus-like particles. *Trends Biotechnol.* 2005.
- [2] Lua LH, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg AP. Bioengineering virus-like particles as vaccines. *Biotechnol Bioeng.* 2014.
- [3] Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. *Methods.* 2006.
- [4] Noad R, Roy P. Virus-like particles as immunogens. *Trends Microbiol.* 2003.
- [5] Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. *Vaccine.* 2012.
- [6] Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. *Nat Rev Immunol.* 2010.
- [7] Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. *Vaccine.* 2012.
- [8] Plotkin SA. History of vaccination. *Proc Natl Acad Sci USA.* 2014.
- [9] Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. *Nat Rev Microbiol.* 2010.
- [10] Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. *Nat Rev Cancer.* 2012.
- [11] D'Amico C, Anticoli S, Giacomini E, Scribano D, Ambrosi C, Mancone C, Faggioni A, Piacentini M, Mastino A, Doria M. A VLP-based vaccine targeting SARS-CoV-2 RBD induces protective immunity. *Nature.* 2021.
- [12] Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. *N Engl J Med.* 2020.
- [13] Lee SY, Lim JS. Design and production of novel antiviral nanoparticles: applications for COVID-19. *Nanomedicine.* 2021.
- [14] Mohsen MO, Gomes AC, Vogel M, Bachmann MF. Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system. *Vaccines.* 2018.
- [15] Roldão A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. *Expert Rev Vaccines.* 2010.
- [16] Cox MM, Izikson R, Post P, Dunkle LM. Influenza virus-like particle vaccines. *Expert Rev Vaccines.* 2015.
- [17] Fuenmayor J, Gòdia F, Cervera L. Production of virus-like particles for vaccines. *New Biotechnol.* 2017.
- [18] Bachmann MF, Zeltins A, Kalnins G, Balke I, Fischer A, Rostaher A, Tars K. Vaccination against emerging infectious diseases: virus-like particles versus other protein platforms. *Nanomedicine.* 2021.